AstraZeneca's Late-Stage Study Win Reinforces Its Hold On Particular Segment Of Lung Cancer Market [Seeking Alpha]
AstraZeneca PLC - American Depositary Shares (AZN)
Last astrazeneca plc - american depositary shares earnings: 2/5 04:00 pm
Check Earnings Report
US:NYSE Investor Relations:
astrazeneca.com/investor-relations.html
Company Research
Source: Seeking Alpha
AstraZeneca's Late-Stage Study Win Reinforces Its Hold On Particular Segment Of Lung Cancer MarketSummaryAstraZeneca announced that it had achieved the second primary endpoint of overall survival in a late-stage study for treating patients with non-small cell lung cancer as maintenance therapy.The meeting of the primary endpoint of overall survival comes on the heels of last year, when AstraZeneca reported that Imfinzi had improved progression-free survival in the same patient population.Imfinzi being used in the unresectable stage 3 NSCLC maintenance therapy segment is expected to earn up to $2.8 billion by 2023.Multiple competitors are also seeking for approval in this same patient population that Imfinzi is targeting in the lung cancer market, but it's still quite some time before that will happen.The ability to improve both overall survival and progression-free survival means that peak sales that are expected for Imfinzi in this part of the lung cancer market should be achieved ac
Show less
Read more
Impact Snapshot
Event Time:
AZN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AZN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AZN alerts
High impacting AstraZeneca PLC - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
AZN
News
- AstraZeneca PLC (NASDAQ: AZN) had its price target raised by analysts at BMO Capital Markets from $80.00 to $82.00. They now have an "outperform" rating on the stock.MarketBeat
- Pharma Stock Roundup: MRK, SNY, AZN, NVS' Q1 Results, Pipeline & Regulatory Updates [Yahoo! Finance]Yahoo! Finance
- AstraZeneca: Strong In A Weak Market [Seeking Alpha]Seeking Alpha
- Regenerative Medicine Market Size Expected to Reach USD 154.05 Bn by 2033 [Yahoo! Finance]Yahoo! Finance
- Fusion (FUSN) to Report Q1 Earnings: Here's What to Expect [Yahoo! Finance]Yahoo! Finance
AZN
Sec Filings
- 4/25/24 - Form 6-K
- 4/11/24 - Form 6-K
- 4/11/24 - Form 6-K
- AZN's page on the SEC website